Revenue distribution by sectors:

• Imaging procedures: approx. 45%
• Diagnostics: approx. 30%
• Advanced Therapies: approx. 15%
• Varian (radiation therapy): approx. 10%

TOP 3 markets and their percentage shares:

• USA: approx. 35%
• Germany: approx. 20%
• China: approx. 15%

Siemens Healthineers AG generates the majority of its revenue from the Imaging Procedures and Diagnostics sectors, which together account for approximately 75% of total revenue. These segments are crucial for positioning the company in the healthcare sector.

The USA remains the largest individual market for Siemens Healthineers, followed by Germany and China. These markets are of strategic importance as they are both technologically advanced and financially strong, ensuring high demand for Siemens Healthineers' products and services.

Production sites of Siemens Healthineers:

• Germany: Headquarters in Erlangen, significant production facilities in Forchheim and Kemnath.
• USA: Important production sites in Newark, Delaware and in the region of Knoxville, Tennessee.
• China: Production site in Shanghai.
• India: Production site in Bengaluru.

Siemens Healthineers produces its products at several international locations to efficiently meet global demand. In Germany, some of the largest and most technologically advanced production facilities are located, focusing on the manufacturing of imaging systems and laboratory diagnostics.

In the USA and China, the company has also established significant production capacities to better serve the North American and Asian markets. These sites are strategically important to optimize supply chains and ensure market proximity.

Strategic Focus:

• Digitalization and AI Integration: Siemens Healthineers is increasingly focusing on integrating Artificial Intelligence and digital solutions into its product range.
• Expansion of the Diagnostics Portfolio: The company plans to expand its offerings in the field of in-vitro diagnostics.
• Global Market Expansion: Focus on growth markets in Asia and Latin America.

Siemens Healthineers pursues a strategy that strongly targets the digitalization of the healthcare sector. By integrating AI into its medical devices and solutions, the company aims to improve efficiency and accuracy in diagnostics and therapy. This is intended not only to optimize patient care but also to open up new revenue streams.

In addition, the company plans to expand its diagnostics portfolio, particularly in the field of in-vitro diagnostics. This expansion is intended to be supported by strategic partnerships and targeted acquisitions to strengthen its market position.

Another strategic focus is on expanding into high-growth markets, especially in Asia and Latin America. These regions offer significant growth opportunities due to the increasing demand for advanced healthcare solutions.

Main materials: Semiconductors, metals, plastics

Countries of origin: USA, China, Germany, Japan

Siemens Healthineers AG, as a leading company in the field of medical technology, imports a variety of raw materials and materials that are essential for the production of their products. The most important materials include semiconductors, metals such as aluminum and copper, and various plastics.

Semiconductors are mainly sourced from the USA and China, as these countries are leading in semiconductor production. Metals such as aluminum and copper are imported both locally in Germany and from international markets like Japan to ensure a secure supply. Plastics are imported from a mix of European and Asian countries, depending on specific requirements and availability.

These import strategies enable Siemens Healthineers to ensure a stable supply chain and maintain the quality of their products.

Market share: 14% in the field of medical imaging diagnostics (2024)
R&D expenses: 1.5 billion euros (2024)
EBIT margin: 17% (2024)

Siemens Healthineers AG has a significant competitive advantage, especially in the field of medical imaging diagnostics, where the company holds a market share of about 14%. This is supported by continuous investments in research and development, which amounted to 1.5 billion euros in 2024. These investments enable the company to develop innovative products and technologies that set it apart from its competitors.

The EBIT margin of 17% demonstrates strong operational efficiency and profitability, indicating effective cost control and a strong market position. Siemens Healthineers also benefits from its global presence and a broad product portfolio, allowing the company to flexibly respond to diverse market requirements.

In summary, Siemens Healthineers' competitive advantage is underpinned by technological leadership, strong financial performance, and a strategic market position.

Institutional investor share: approx. 70% (estimated for 2025 based on historical data)

Insider purchases/sales: No significant transactions known (as of 2025)

The institutional investor share at Siemens Healthineers AG traditionally stands at around 70%. This high participation reflects institutional investors' confidence in the company's long-term stability and growth potential.

No significant insider purchases or sales are known for the year 2025. This suggests that the management and other insiders are currently not making significant changes to their stake in the company, indicating a stable trust in the current corporate strategy.

Market Share Siemens Healthineers AG: Estimate 10-12% (2025)

Main Competitors and their Market Shares:

1. GE HealthCare Technologies Inc. - Estimate 12-14%
2. Philips Healthcare - Estimate 10-11%
3. Roche Diagnostics - Estimate 9-10%
4. Abbott Laboratories - Estimate 8-9%
5. Medtronic - Estimate 7-8%
6. Thermo Fisher Scientific - Estimate 6-7%
7. Danaher Corporation - Estimate 5-6%

Siemens Healthineers AG is a significant player in the field of medical technology and diagnostics with a solid market share. The company's "moat" consists of its strong innovation capabilities, a wide product range, and a global presence. Siemens Healthineers benefits from its close connection to Siemens AG, providing access to extensive resources and technologies.

Compared to its competitors, Siemens Healthineers has a strong focus on research and development, which can be considered a significant advantage. However, GE HealthCare and Philips Healthcare are also well-positioned, especially due to their comprehensive solutions and established market presence.

Competition in the industry is intense, and while Siemens Healthineers has a robust moat, companies like GE HealthCare and Philips Healthcare also have significant competitive advantages due to their long-standing experience and innovation capabilities.

Revenue growth: 8.5% (2024) Profit growth: 10.2% (2024) Research and development ratio: 7% of revenue (2024)

Siemens Healthineers AG achieved solid revenue growth of 8.5% in 2024, driven by strong demand for medical technologies and services. The profit growth of 10.2% during the same period indicates that the company is operating efficiently and was able to increase its profitability.

Another positive aspect is the investment in research and development, which accounts for 7% of revenue. This suggests that Siemens Healthineers continues to invest in innovations to strengthen its market position and secure future growth.

Additionally, the company has expanded its global presence, especially in high-growth markets such as Asia and North America, further increasing its future growth potential.

Overall, these factors indicate that Siemens Healthineers AG is an attractive investment opportunity, especially for investors interested in long-term growth.

Dividend yield: 2.5% (estimated for 2025)
Dividend history: Continuous distribution in recent years

Siemens Healthineers AG has regularly distributed dividends to its shareholders in recent years. The company's dividend policy is aimed at providing shareholders with a stable and reliable return.

The estimated dividend yield for 2025 is around 2.5%. This estimate is based on the company's past distribution policy and financial results. Siemens Healthineers has demonstrated solid financial performance in the past, indicating a reliable dividend payment in the future as well.

The continuity of dividend payments and the financial stability of the company suggest that the distribution is likely to remain reliable in the coming years.